Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder

Purpose

This study examines the effects of e-cigarette (EC) flavors among adults with opioid use disorder (OUD) receiving buprenorphine treatment who currently use e-cigarettes. Participants will complete a brief session in which they will smell and rate 11 EC flavors based on appeal, sensory characteristics, and likelihood of future use. Researchers will examine how different flavor profiles influence the appeal, positive subjective effects, and reinforcing potential of EC flavors in this population. The goal of the study is to identify one or more EC flavors that may enhance the acceptability and reinforcing effects of ECs as a potential harm-reduction strategy among adults with OUD receiving buprenorphine treatment. Participants must be current EC users, former daily combustible cigarette smokers, at least 21 years old, and currently receiving buprenorphine treatment for OUD.

Conditions

  • Nicotine Use Disoder
  • Opioid Use Disorder

Eligibility

Eligible Ages
Over 21 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults aged 21 years or older. - Current e-cigarette users who report e-cigarette use on ≥20 of the past 30 days. - Former daily cigarette smokers who currently smoke on ≤19 days per month and smoke no more than 5 cigarettes per day. - Diagnosed with opioid use disorder (OUD). - Currently receiving buprenorphine treatment for OUD.

Exclusion Criteria

Study Design

Phase
Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Recruiting Locations

Prisma Health Recovery Clinic-Greenville
Greenville, South Carolina 29605
Contact:
Alain Litwin, MD
(864) 455-5994
alain.litwin@prismahealth.org

More Details

Status
Recruiting
Sponsor
Prisma Health-Upstate

Study Contact

Irene Pericot-Valverde, PhD
18549998005
iperico@clemson.edu

Detailed Description

This study examines the effects of e-cigarette flavors among adults with opioid use disorder receiving buprenorphine treatment.